A875 con metotrexato. Se consideraron horizontes temporales de uno, cinco, diez años y toda la vida del paciente. La unidad de resultado fueron años de vida ajustados por calidad (AVAC). El puntaje inicial del HAQ (Health Assessment Questionnaire) como respuesta clínica de corto y largo plazo se tomó de la literatura y se realizaron comparaciones indirectas. Los costos (expresados en bolívares venezolanos de 2014, Bs.) fueron obtenidos de fuentes oficiales y manuales tarifarios. Para el caso de tofacitinib se asumió paridad de precio con etanercept. La tasa de descuento, 5% para costos y desenlaces. ResultAdos: Para el horizonte temporal de toda la vida del paciente, los costos totales esperados fueron: adalimumab Bs. 2.248.884; etanercept Bs. 1.998.582; infliximab Bs 2.283.026 y tofacitinib Bs. 1.909.658. Los resultados en términos de AVAC fueron: adalimumab 10,4767; etanercept 10,6700; infliximab 10,7172 y tofacitinib 10,9100. ConClusiones: Bajo los supuestos del modelo, el esquema de tratamiento que inicia con tofacitinib es una alternativa costo-ahorradora comparado con los esquemas que inician con adalimumab e infliximab en todos los horizontes temporales considerados. Comparado con el esquema que inicia con etanercept es una alternativa costo-efectiva en los horizontes de 5 y 10 años y costo-ahorradora en los horizontes de 1 año y toda la vida del paciente. PMS8AnáliSiS de CoSto efeCtividAd y CoSto UtilidAd de RitUxiMAb CoMo tRAtAMiento en PACienteS Con ARtRitiS ReUMAtoide, Ante el fAllo o intoleRAnCiA en PRiMeRA líneA de Un Anti-tnf, en el Contexto venezolAno
perform the QoL and loss of productivity Survey, participants completed a selfadministered questionnaire that included measures of generic and weight-specific quality of life, perceived health, physical function, depressive symptoms, and body mass index (BMI) was determined. Descriptive and inferential statistical analysis was don. Body Mass Index (BMI) was define as independent variable to examine differences in self-reported perceived QoL Results: a total of 160 patients was included with age between 18 to 67 years. 44.4 % married, 32.5 % single 94.4 % has familiar precedents of obesity and 78.8 % has had formal and informal previous treatments. BMI distribution: 39 % overweight, 40 % were obese and obesity grade is as follow: I 44.4% and the IInd 44.4 %, the IIIrd 11.2 %. 85.6 % of the patients presents at least for comorbility. 5 % are unemployed, and 9.4 % had been absent at least to working. The average of the VAS was 76.4 and it has a negative statistically significant correlation (p= 0.01) with obesity class and BMI, On having evaluated if correlation exists between the VAS and the age obtained a positive value (p of 0.001). The Comorbidity was a factor that it was affecting. In higher Obesity reported lower measures of perceived health status and physical functioning ConClusions: In this sample obesity and its comorbidities were associated with VAS general health perception.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.